BCM
IBB icon

Blume Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Blume Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.16M Sell
27,113
-375
-1% -$64.5K 0.75% 43
2026
Q1 		$4.64M Sell
27,488
-2,150
-7% -$368K 0.79% 43
2025
Q4 		$5M Sell
29,638
-21,437
-42% -$3.48M 0.91% 39
2025
Q3 		$7.37M Sell
51,075
-110
-0.2% -$15K 1.4% 29
2025
Q2 		$6.48M Buy
51,185
+16
+0% +$1.96K 1.3% 31
2025
Q1 		$6.54M Sell
51,169
-340
-0.7% -$46.1K 1.46% 28
2024
Q4 		$6.81M Sell
51,509
-190
-0.4% -$26.7K 1.53% 27
2024
Q3 		$7.53M Sell
51,699
-505
-1% -$73.1K 1.68% 28
2024
Q2 		$7.17M Sell
52,204
-200
-0.4% -$26.7K 1.73% 27
2024
Q1 		$7.19M Sell
52,404
-382
-0.7% -$52.2K 1.74% 27
2023
Q4 		$7.17M Sell
52,786
-765
-1% -$93.3K 1.87% 21
2023
Q3 		$6.55M Sell
53,551
-867
-2% -$110K 1.94% 17
2023
Q2 		$6.91M Sell
54,418
-105
-0.2% -$13.6K 2.02% 20
2023
Q1 		$7.04M Sell
54,523
-4,565
-8% -$598K 2.23% 13
2022
Q4 		$7.76M Sell
59,088
-1,690
-3% -$218K 2.62% 10
2022
Q3 		$7.11M Sell
60,778
-4,450
-7% -$553K 2.68% 13
2022
Q2 		$7.67M Buy
65,228
+4,320
+7% +$513K 3.03% 9
2022
Q1 		$7.94M Buy
60,908
+5,056
+9% +$659K 2.62% 13
2021
Q4 		$8.52M Sell
55,852
-315
-0.6% -$48.8K 2.81% 12
2021
Q3 		$9.08M Buy
56,167
+2,228
+4% +$375K 3.32% 9
2021
Q2 		$8.83M Buy
53,939
+4,793
+10% +$738K 3.23% 10
2021
Q1 		$7.4M Sell
49,146
-1,187
-2% -$189K 2.91% 14
2020
Q4 		$7.63M Sell
50,333
-2,135
-4% -$305K 3.26% 11
2020
Q3 		$7.11M Sell
52,468
-886
-2% -$120K 3.6% 10
2020
Q2 		$7.29M Sell
53,354
-2,674
-5% -$341K 4.04% 7
2020
Q1 		$6.04M Sell
56,028
-2,555
-4% -$294K 3.87% 9
2019
Q4 		$7.06M Sell
58,583
-6,055
-9% -$676K 3.45% 9
2019
Q3 		$6.43M Sell
64,638
-200
-0.3% -$20.9K 3.21% 10
2019
Q2 		$7.07M Sell
64,838
-325
-0.5% -$34.6K 3.58% 6
2019
Q1 		$7.29M Sell
65,163
-330
-0.5% -$36.2K 3.82% 6
2018
Q4 		$6.32M Sell
65,493
-1,495
-2% -$159K 3.61% 5
2018
Q3 		$8.17M Sell
66,988
-988
-1% -$116K 4.27% 4
2018
Q2 		$7.46M Sell
67,976
-1,150
-2% -$123K 4.07% 3
2018
Q1 		$7.38M Sell
69,126
-3,765
-5% -$417K 4.1% 6
2017
Q4 		$7.78M Sell
72,891
-225
-0.3% -$24.1K 3.98% 6
2017
Q3 		$8.13M Buy
73,116
+180
+0.2% +$19.2K 4.3% 5
2017
Q2 		$7.54M Buy
72,936
+645
+0.9% +$63.5K 4.28% 5
2017
Q1 		$7.07M Sell
72,291
-72
-0.1% -$6.89K 4.09% 6
2016
Q4 		$6.4M Buy
72,363
+1,185
+2% +$108K 3.85% 8
2016
Q3 		$6.87M Buy
71,178
+480
+0.7% +$45.7K 4.21% 7
2016
Q2 		$6.06M Buy
70,698
+7,395
+12% +$664K 4% 7
2016
Q1 		$5.5M Buy
63,303
+7,005
+12% +$626K 3.8% 9
2015
Q4 		$6.35M Sell
56,298
-1,992
-3% -$216K 4.49% 7
2015
Q3 		$5.89M Sell
58,290
-9,390
-14% -$1.13M 4.78% 6
2015
Q2 		$8.32M Sell
67,680
-2,400
-3% -$287K 6.3% 2
2015
Q1 		$8.02M Sell
70,080
-360
-0.5% -$39.7K 5.56% 2
2014
Q4 		$7.12M Buy
70,440
+840
+1% +$81.6K 5.02% 5
2014
Q3 		$6.35M Buy
69,600
+150
+0.2% +$13.2K 4.94% 6
2014
Q2 		$5.95M Buy
69,450
+5,055
+8% +$398K 4.67% 7
2014
Q1 		$5.07M Sell
64,395
-9,810
-13% -$817K 4.03% 7
2013
Q4 		$5.62M Buy
+74,205
New +$5.26M 4.65% 6

Other funds holding IBB

Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
WA
WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return
GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
AP
Appleton Partners Boston, Massachusetts $1.63B AUM 38.57% 1-Year Est. Return
FMI
Factory Mutual Insurance Waltham, Massachusetts $10.6B AUM 34.1% 1-Year Est. Return

Blume Capital Management's IBB Position: Q2 2026 in Review

Blume Capital Management reduced its iShares Biotechnology ETF (IBB) stake by 1.4% in Q2 2026, selling an estimated $64.5K and leaving 27,113 shares worth $5.16M. The position accounts for 0.75% of the portfolio, ranked #43.

Blume Capital Management first reported a position in IBB in Q4 2013 and has held it in 51 quarters since. The position peaked at $9.08M in Q3 2021. 421 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Blume Capital Management held 27,113 shares of iShares Biotechnology ETF worth $5.16M as of Q2 2026.
  • Blume Capital Management sold 375 iShares Biotechnology ETF shares in Q2 2026, an estimated $64.5K.
  • iShares Biotechnology ETF made up 0.75% of Blume Capital Management's portfolio in Q2 2026, its #43 holding.
  • Blume Capital Management first reported a position in iShares Biotechnology ETF in Q4 2013 and has held it in 51 quarters since.
  • Blume Capital Management's iShares Biotechnology ETF position peaked at $9.08M in Q3 2021.
  • 421 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Blume Capital Management's 13F filing for Q2 2026, filed 27 Jul 2026.